No, an accidental extra 140 mg dose of Repatha will NOT elevate blood glucose in a patient with controlled diabetes.
Repatha (evolocumab) is a PCSK9 inhibitor that does not adversely affect glycemic control, and an accidental extra dose poses no risk of worsening diabetes.
Evidence from FDA Drug Label
The FDA label for Repatha explicitly addresses diabetes concerns. In the large cardiovascular outcomes trial involving 27,525 patients, diabetes mellitus occurred at nearly identical rates: 8.8% with Repatha versus 8.2% with placebo 1. This minimal difference demonstrates that even with chronic therapeutic dosing, Repatha does not meaningfully impact diabetes incidence or control.
Critically, no clinically relevant changes in fasting plasma glucose or HbA1c were observed in clinical trials 1. This finding held true across multiple studies and dosing regimens.
Supporting Clinical Trial Data
Multiple high-quality studies confirm Repatha's glycemic neutrality:
Pooled analysis of 10 ODYSSEY trials (n=3,448 non-diabetic patients) found no effect on new-onset diabetes with hazard ratios of 0.64 vs placebo and 0.55 vs ezetimibe, with no differences in fasting glucose or HbA1c over 6-18 months 2
Pooled safety analysis of 14 trials (n=5,234 patients, 30% with diabetes) showed no increase in HbA1c or fasting plasma glucose regardless of diabetes status 3
Studies specifically in type 2 diabetes patients consistently reported no clinically significant changes in glycemic parameters or need for antihyperglycemic medication adjustments 4, 5, 6
Mechanism and Reassurance
PCSK9 inhibitors work by blocking PCSK9 protein, which increases LDL receptor recycling on hepatocytes to lower LDL cholesterol. This mechanism has no direct effect on insulin secretion, insulin sensitivity, or glucose metabolism. Unlike statins, which have modest adverse effects on glycemic control, PCSK9 inhibitors demonstrate glycemic neutrality.
Clinical Management of Accidental Overdose
For an accidental extra 140 mg dose:
- No specific intervention is required for diabetes management
- Continue routine glucose monitoring as previously established
- The patient can resume their normal Repatha dosing schedule
- Watch for the medication's known adverse effects (injection site reactions, nasopharyngitis, upper respiratory infections) rather than glycemic changes 1
Important Caveat
The only diabetes-related concern in the FDA label is that diabetes mellitus was listed as a common adverse reaction (>5%) in the cardiovascular outcomes trial, but this reflects disease progression in a high-risk population, not a drug effect—the placebo rate was nearly identical (8.8% vs 8.2%) 1.